DRUG
Bright Minds Biosciences Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Bright Minds Biosciences Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
No other changes.
No other changes.
Annual filing, covered
20-F parsed · Dec 31 '24
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Dec 31 '24
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Bright Minds Biosciences Inc.'s 3 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Bright Minds Biosciences Inc.'s 3 closest co-movers, none share that code.
Bright Minds Biosciences Inc.
18.65
−2.90 · −13.44%
—
News
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $94.8M | 14.50% | — |
| Cormorant | $63.2M | 9.66% | −15.04% |
| BlackRockindex-like | $48.2M | 7.37% | +10.33% |
| Vivo Capital | $39.1M | 5.98% | 0.00% |
| Vestal Point Capital | $38.3M | 5.85% | +10.70% |
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $94.8M | 14.50% | — |
| Cormorant | $63.2M | 9.66% | −15.04% |
| BlackRockindex-like | $48.2M | 7.37% | +10.33% |
| Vivo Capital | $39.1M | 5.98% | 0.00% |
| Vestal Point Capital | $38.3M | 5.85% | +10.70% |
—
—
Expected move
No implied move.